Axsome Therapeutics Announces Settlement Resolving All SUNOSI® Patent Litigation
Axsome Therapeutics resolved all SUNOSI patent litigation through a settlement allowing generic sales from 2040, contingent on FDA approval.Summary
Axsome Therapeutics, Inc. (NASDAQ: AXSM) announced the resolution of all pending patent litigation related to its product SUNOSI (solriamfetol) via a settlement agreement with the remaining first-to-file generic applicant. The agreement permits five companies to sell generic versions of SUNOSI starting on or after September 1, 2040 (if pediatric exclusivity is granted) or March 1, 2040 (if not), subject to FDA approval. No further SUNOSI patent litigation remains. The settlement requires submission to U.S. regulatory bodies. Axsome, a biopharmaceutical firm focused on CNS disorders, highlighted its mission to address neurological and psychiatric conditions affecting over 150 million people in the U.S., with FDA-approved treatments for depression, dementia-related agitation, sleep disorders, and migraine.
(Source：Investing News Network (inn))